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Outcome Prediction of Septal
Ablation in Patients With
Hypertrophic Cardiomyopathy
Still a Long Way to Go*
Paul Sorajja, MD, Rick A. Nishimura, MD
Rochester, Minnesota
Dynamic left ventricular outflow tract (LVOT) obstruction
is common in patients with hypertrophic cardiomyopathy,
resulting from a complex interplay of myocardial hypertro-
phy, ventricular load, as well as drag and Venturi effects on
the mitral valve (1). Although its clinical significance has
been debated, recent investigations have shown that dy-
namic obstruction is predictive of outcome as well as
contributing to limiting symptoms, the latter of which abate
with appropriate therapeutic intervention (1,2). These es-
tablished therapies include negative inotropic agents and,
for those patients with refractory symptoms, surgical myec-
tomy. Surgical myectomy results in complete abolition of
the gradient, durable symptom relief in 90% of patients,
with minimal operative risk when performed in experienced
centers (3).
See page 1030
Septal ablation emerged in 1995 and generated immedi-
ate fervor, becoming widely adopted by invasive cardiovas-
cular specialists (4). Although there has been no systematic
case reporting of septal ablation, anecdotal estimates suggest
that the number of patients who have had this catheter-
based procedure in the past 15 years has far exceeded the
total number of surgical myectomies performed over 5
decades. However, as the complications and longer-term
results of septal ablation have been carefully studied, it is
apparent that this procedure is not always an equal alterna-
tive to septal myectomy (5). The question now is the
ultimate role of septal ablation in clinical practice today.
Undoubtedly, septal ablation results in a decrease in the
gradient and relief of symptoms in many patients. However,
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elevant to the contents of this paper to disclose.there is a subset of patients in whom significant residual
gradients and suboptimal relief of symptoms remain after
ablation. Despite incremental additions to the technique
(such as the use of echo contrast with attempt to identify the
proper septal perforator artery), it is still difficult to select
patients in whom septal ablation will be effective. There is a
known morbidity and mortality with creating an infarction
from septal ablation, as well as the controversial potential for
enhancing the occurrence of life-threatening ventricular
arrhythmias (6). In addition, there is a higher frequency of
complications when surgical myectomy is performed after
patients have had unsuccessful septal ablation (7). Thus, if
we could identify those patients who would not benefit from
septal ablation, they would be best served by proceeding
directly to septal myectomy.
The current study by Almasood et al. (8), which is
reported in this issue of JACC: Cardiovascular Interventions,
is an attempt to advance our understanding of appropriate
patient selection for septal ablation. In this study, the
investigators examined 120 patients who underwent septal
ablation at their institution. They report that examination of
the time for gradient reduction during balloon occlusion of
a septal artery correlates with the magnitude of the final
gradient response immediately after septal ablation. If the
study methodology and their conclusions indeed were
sound, the clinical implication of this finding is that
transitory balloon occlusion could be used to predict clinical
success with septal ablation.
This study, although valid in its aim, has significant
limitations. Importantly, the methods for LVOT gradient
assessment used in the study can be erroneous. Severe
pressure damping occurs from the use of end-hole coronary
catheters that contain angioplasty balloons, leading to inac-
curate measurements of aortic pressure and the LVOT
gradient. Great attention to the potential for these artifacts
is needed to mitigate their confounding effects. The LVOT
gradient in patients with hypertrophic cardiomyopathy also
is highly dynamic and exquisitely dependent on ventricular
load and the contractile state, easily varying on a beat-to-
beat basis. Therefore, provocative methods may be required
to assess the true severity of the LVOT obstruction and,
consequently, the magnitude of its reduction, especially in
those patients with labile gradients. In addition, the ven-
tricular septum frequently receives a rich supply of blood
flow from other septal perforator arteries not occluded by
the balloon. This supply might limit myocardial ischemia
and lead to inaccuracies in estimating the impact of balloon
occlusion on acute gradient reduction.
Most importantly, the present study by Almasood et al.
(8) focuses on the short-term effects of alcohol ablation.
Acute hemodynamic results (i.e., the measurement of “suc-
cess” in this study) have not been shown to predict the
ultimate clinical outcome of septal ablation. A temporary
acute decrease in the gradient, with a return in gradient
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1036following recovery of the myocardial function after several
days has been shown. There is left ventricular remodeling
that will occur after alcohol ablation, which can result in
regression of myocardial hypertrophy both at the ventricular
septum and remote from the ablation site (9). Thus, it will
be critical to know the long-term outcome of these patients
to determine the feasibility of applying the investigators’
methodology to the decision-making progress.
Of note, the data in the present study by Almasood et
al. (8) support the concept that septal ablation is not
lways equivalent to septal myectomy. In 9% of the
atients undergoing the procedure, the ablation was not
ctually performed. Among the patients who did undergo
lcohol ablation, the average residual gradient immedi-
tely after alcohol ablation was 17 mm Hg, which is
reater than that observed with surgical myectomy (typ-
cally 5 mm Hg). Significant residual gradients that do
ot improve in follow-up cause incomplete relief of
ymptoms and continued limitation of activity, especially
n the younger, more active individuals, as observed in
ur previous investigations (10).
Selection for alcohol ablation entails complex decision
aking, with consideration of not only the potential for
cute hemodynamic success but also long-term conse-
uences. Certainly, patient desire to avoid open-heart sur-
ery is an important component of the choice of therapy.
evertheless, the ultimate goal of septal reduction therapy,
ia either surgical myectomy or alcohol ablation, is to
rovide durable relief of LVOT obstruction and symptoms
ith either a beneficial or no adverse impact on patient
ongevity. To know the ultimate role of septal ablation in
he treatment armamentarium, we still need further studies
ot only to predict those patients who will respond to septal
blation, but also to understand the long-term outcome of
reating a localized myocardial infarction in this disease. It
s also important to continue to support the recommenda- mtion that evaluation for septal reduction therapy be done in
a tertiary center with established multidisciplinary expertise
in the care of these patients.
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